Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: Sparks Grant - General Pool

University of Alberta

$75,000.00

A novel rapid, liquid biopsy early stage lung cancer diagnostic test

FY 2020-21

Summary
Lung cancer is the leading cause of cancer-related deaths worldwide, with ~ 1.69 million deaths/year. In Canada, more than 20,000 people die/year from lung cancer. The five-year survival rate is just 17%, due largely in part to the delayed detection of lung cancer. However, when lung cancer is detected and resected in stage 1, the 10-year survival rate is increased to >80%. A non-invasive, rapid and sensitive test for early stage lung cancer is critical for improved patient survival rates. Our goal is to develop a low cost, highly sensitive and accurate lung cancer test for patient screening. The metabolite test will be based on using technologies that are routinely used in clinical diagnostic laboratories. The test will be minimally invasive, requiring only a small amount of blood for analysis and will detect lung cancer at stage I or stage II, which is when it is most treatable. This project builds off exciting early stage lung cancer biomarker discoveries in our lab. Cancer cells have a fundamentally different metabolism than normal cells. This difference is manifested in the metabolites, or chemicals, they produce. We will use advanced technologies developed in our lab to detect and measure these metabolites (metabolomics) in blood samples. We will develop a kit-based test for measuring a unique set of metabolites for early stage lung cancer. The kit will be easily transferable to diagnostic labs across the country, beginning with Alberta Precision Labs. Early stage detection will have unprecedented impact not only on patient treatment but survival rates and healthcare costs. Lung cancer treatment averages >$70,000/patient. A blood-based test as a standard screening tool for high-risk populations represents a potential cost savings of >$150 million/year in hospital care and mortality costs for lung cancer in Canada. Our test will enable physicians to make evidence-based prevention and treatment decisions. A blood-based test makes sample collection very simple and is more likely to encourage patient participation in screening programs.
Program
Operating Grant: Sparks Grant - General Pool
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
442518
Name
Wishart David S
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Cancer Society - National Office (Toronto); Brain Canada Foundation (Montreal, Québec)
Prcname2
Special Cases
Projecttitle
A novel rapid, liquid biopsy early stage lung cancer diagnostic test
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$75,000
Cihrequipment2
$0
Programname2
Operating Grant: Sparks Grant - General Pool
Keyworddelim
Early Stage Diagnosis; Lung Screening; Machine Learning; Mass Spectrometry; Metabolomics; Novel Biomarker Panel; Test Kit
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide, with ~ 1.69 million deaths/year. In Canada, more than 20,000 people die/year from lung cancer. The five-year survival rate is just 17%, due largely in part to the delayed detection of lung cancer. However, when lung cancer is detected and resected in stage 1, the 10-year survival rate is increased to >80%. A non-invasive, rapid and sensitive test for early stage lung cancer is critical for improved patient survival rates. Our goal is to develop a low cost, highly sensitive and accurate lung cancer test for patient screening. The metabolite test will be based on using technologies that are routinely used in clinical diagnostic laboratories. The test will be minimally invasive, requiring only a small amount of blood for analysis and will detect lung cancer at stage I or stage II, which is when it is most treatable. This project builds off exciting early stage lung cancer biomarker discoveries in our lab. Cancer cells have a fundamentally different metabolism than normal cells. This difference is manifested in the metabolites, or chemicals, they produce. We will use advanced technologies developed in our lab to detect and measure these metabolites (metabolomics) in blood samples. We will develop a kit-based test for measuring a unique set of metabolites for early stage lung cancer. The kit will be easily transferable to diagnostic labs across the country, beginning with Alberta Precision Labs. Early stage detection will have unprecedented impact not only on patient treatment but survival rates and healthcare costs. Lung cancer treatment averages >$70,000/patient. A blood-based test as a standard screening tool for high-risk populations represents a potential cost savings of >$150 million/year in hospital care and mortality costs for lung cancer in Canada. Our test will enable physicians to make evidence-based prevention and treatment decisions. A blood-based test makes sample collection very simple and is more likely to encourage patient participation in screening programs.
Competitiondate
202010
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wishart, David S
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $75,000~ $0~
University of Alberta - $75,000 Grant (2020-21) | Canada Spends